

# The burden of rhinitis in Australia

**First published:** 02/02/2015

**Last updated:** 22/02/2024

Study

Planned

## Administrative details

### EU PAS number

EUPAS8507

---

### Study ID

27684

---

### DARWIN EU® study

No

---

### Study countries

 Australia

---

### Study description

A set of three studies that aim to evaluate the burden of rhinitis on healthcare in Australia by assessing the real life treatment of rhinitis using prescribing and over the counter information, and the effect of introducing Dymista to the Australian market

---

## Study status

Planned

# Research institutions and networks

## Institutions

### Observational & Pragmatic Research Institute Pte (OPRI)

 United Kingdom

**First published:** 06/10/2015

**Last updated:** 19/08/2024

**Institution**

**Educational Institution**

**Laboratory/Research/Testing facility**

**ENCePP partner**

## Contact details

### Study institution contact

David Price [dprice@opri.sg](mailto:dprice@opri.sg)

**Study contact**

[dprice@opri.sg](mailto:dprice@opri.sg)

### Primary lead investigator

David Price

**Primary lead investigator**

# Study timelines

## **Date when funding contract was signed**

Planned: 30/01/2015

---

## **Study start date**

Planned: 06/02/2015

---

## **Data analysis start date**

Planned: 14/02/2015

Actual: 18/03/2015

---

## **Date of final study report**

Planned: 31/05/2015

# Sources of funding

- Pharmaceutical company and other private sector

# More details on funding

MEDA Australia

# Study protocol

[R01414\\_Study 1 Rhinitis treatment](#)

[patterns\\_Protocol\\_2015\\_V10.For\\_EnCEPP\\_02Feb15.pdf](#) (491.59 KB)

[R01414\\_Study 1 Rhinitis treatment patterns\\_Protocol\\_2015\\_V11.pdf](#) (585.11 KB)

# Regulatory

**Was the study required by a regulatory body?**

Unknown

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Other

**If 'other', further details on the scope of the study**

Real life treatment of rhinitis

**Main study objective:**

To evaluate the burden of rhinitis on healthcare in Australia by assessing the real life treatment of rhinitis using prescribing and over the counter information, and the effect of introducing Dymista to the Australian market

## Study Design

## **Non-interventional study design**

Cohort

# Study drug and medical condition

## **Medical condition to be studied**

Rhinitis allergic

# Population studied

## **Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

## **Estimated number of subjects**

50000

# Study design details

## **Outcomes**

1) To assess the number of therapies (single vs. multiple drugs) used to treat rhinitis in Australia  
2) To describe the combination of therapies used to treat rhinitis in Australia  
3) To investigate the influence of OTC medications on the count and combination of therapies used to treat rhinitis in Australia, 4) To

investigate the seasonality of rhinitis treatment patterns<sup>5</sup>) To estimate the cost of rhinitis treatment in Australia<sup>6</sup>) To investigate the relationship between rhinitis treatment patterns and co-morbid asthma treatment

---

### **Data analysis plan**

- Count of therapies will be reported as means and standard deviation SD, and/or median and inter-quartile range (25th and 75th percentiles) along with minimum and maximum values. Moreover, count of therapies will be presented as single, multiple and total number of therapies.
- Within the multiple therapy patients group, the combination of different drug will be reported as absolute numbers as well as proportions and percentages.
- Prescribed and over-the-counter medications will be reported as absolute numbers as well as proportions and percentages.
- Time series analysis will be used to explore seasonality of rhinitis treatment patterns over the study period
- The cost of rhinitis treatment will be reported as mean and median purchase (in Austrian dollars) along with their inter-quartile range and minimum and maximum values of purchases.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

**Data source(s), other**

NostraData Australia

---

**Data sources (types)**

[Drug dispensing/prescription data](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No